Introduction: Data were collected for patients with advanced NSCLC treated with PD-1 / PD-L1 inhibitors from 2016 to 2019 at the Pulmonology Unit of the Macerata General Hospital. Objectives: The primary endpoint was overall survival (OS), secondary endpoints were progression-free survival (PFS), objective response rates (ORR), disease control (DCR) and safety. Methods: Efficacy was evaluated according response assessment criteria in solid tumors (iRECIST). Survival curves were generated by Kaplan-Meier test and the log-rank test for comparing different factors on PFS and OS. Results: The average follow-up time was 16 months. At the end of follow-up, 24 patients (61.5%) were continuing immunotherapy and 7 patients (17.9%) had died. Twenty-six patients (66.7%) used PD-1/PD-L1 inhibitors as first-line treatment and 7 patients (17.9%) as a second-line treatment, only 6 patients (15.4%) as third-line treatment. Complete response occurred in 1 case (2.6%), partial response in 10 cases (25.6%), stable disease in 16 cases (41.0%), progressive disease in 12 cases (30.8%). The ORR was 28.2% and the DCR was 69.2%. The median PFS was 18.7 months (95% CI 5.9-36,1 months). Conclusions: Treatment with PD-1/PD-L1 inhibitors shown to be effective in patients with advanced NSCLC in a real-life context, the efficacy of the treatment was independent of the age. Factors associated with lower survival were the presence of brain or liver metastases or previous treatment with a tyrosine kinase inhibitor (TKI) drug.